Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Puja C. Arora, MD, Victor M. Orellana-Noia, MD, Abeer Alfaraj, MBBS, Wenzinger Christopher, MD, Sandra Monson, PhD, Gina Petroni, PhD, Craig A. Portell, MD, Michael E. Williams, MD

Blood (2018) 132 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2018-99-117651

Published: 2018

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

The Incidence and the Risk Factors of Bowel Perforation Due to Chemotherapy in Gastrointestinal Diffuse Large B Cell Lymphoma

Takuro Matsumoto, MD, Yuhei Shibata, MD, Nobuhiko Nakamura, MD PhD, Hiroshi Nakamura, MD, Soranobu Ninomiya, MD PhD, Junichi Kitagawa, MD PhD, Yasuhito Nannya, MD PhD, Masahito Shimizu, MD PhD, Takeshi Hara, MD PhD, Hisashi Tsurumi, MD PhD

Blood (2015) 126 (23): 1515.

https://doi.org/10.1182/blood.V126.23.1515.1515

Published: 2015

Journal Articles

Outcome of Gastric Diffuse Large B-Cell Lymphoma and Usefulness of PET-CT in Detecting Gastric Lesion

Tomohiro Kadota, MD, Sachiko Seo, MD PhD, Yoshihiro Nakagami, MD, Hiroe Fuse, MD, Yujiro Ueda, MD, Genichiro Ishii, MD PhD, Kuniaki Itoh, MD, Tomonori Yano, MD, Kazuhiro Kaneko, MD PhD, Kunihiro Tsukasaki, MD, PhD

Blood (2015) 126 (23): 2715.

https://doi.org/10.1182/blood.V126.23.2715.2715

Published: 2015

Journal Articles

Pediatric Hemophagocytic Lymphohistocytosis (HLH): A Single Institution Experience in the Diagnosis and Management of This Variable Disease

Hawazen S. Alsaedi, MD, Michael Stump, MD, Wenzinger Christopher, MD, Lazarchick John, MD, Jennifer Jaroscak, MD

Blood (2014) 124 (21): 4982.

https://doi.org/10.1182/blood.V124.21.4982.4982

Published: 2014

Journal Articles

An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease

Frits Van Rhee, Corey Casper, Peter M Voorhees, Luis E Fayad, Helgi van de Velde, Jessica Vermeulen, Xiang Qin, Ming Qi, Brenda Tromp, Razelle Kurzrock

Blood (2013) 122 (21): 1806.

https://doi.org/10.1182/blood.V122.21.1806.1806

Published: 2013

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, Michael LeBlanc, Brent Farnsworth, Maria Iannone, Martha J. Glenn, Richard I. Fisher, Thomas P. Miller

Blood (2012) 120 (6): 1210–1217.

https://doi.org/10.1182/blood-2012-04-423079

Published: 2012

Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 864.

https://doi.org/10.1182/blood.V116.21.864.864

Published: 2010

Journal Articles

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Alison T. Stopeck, MD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Brent Farnsworth, DO, Michael LeBlanc, Ph.D., Maria Iannone, MS, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2010) 116 (21): 591.

https://doi.org/10.1182/blood.V116.21.591.591

Published: 2010

Journal Articles

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Natalie Scott Callander, MD, Stephanie Markovina, BA, Mark B. Juckett, MD, Elizabeth Wagner, MA, Jill Kolesar, Walter Longo, Eliot C. Williams, MD, PhD, Kyungmann Kim, Jae Werndli, BSc, MSc, Shigeki Miyamoto, PhD

Blood (2009) 114 (22): 3885.

https://doi.org/10.1182/blood.V114.22.3885.3885

Published: 2009

Journal Articles

Response of Patients with Aggressive Non Hodgkin's Gastro Intestinal Tract Lymphoma to Upfront Rituximab Based Chemotherapy: A Single Institution Experience.

Bety Ciobanu, MD, Shylendra B Sreenivasappa, MD, Mousami Shah, Barbara Yim, Pharm, D, Rosalind Catchatourian, MD

Blood (2009) 114 (22): 4791.

https://doi.org/10.1182/blood.V114.22.4791.4791

Published: 2009

Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Laura McBride, Deborah Doss, Gail Larkins, Christian Jacques, Arlene Donaldson, Kenneth C. Anderson

Blood (2009) 114 (22): 301.

https://doi.org/10.1182/blood.V114.22.301.301

Published: 2009

Journal Articles

Clinicopathologic Analysis of Primary Gastrointestinal T-Cell Lymphoma with a Special Reference to Intestinal and Gastric Type in Japan.

Hideko Yamamoto, Keitaro Matsuo, Hidemi Goto, Shigeo Nakamura, MD

Blood (2008) 112 (11): 1782.

https://doi.org/10.1182/blood.V112.11.1782.1782

Published: 2008

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

NARROW

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

The Incidence and the Risk Factors of Bowel Perforation Due to Chemotherapy in Gastrointestinal Diffuse Large B Cell Lymphoma

Outcome of Gastric Diffuse Large B-Cell Lymphoma and Usefulness of PET-CT in Detecting Gastric Lesion

Pediatric Hemophagocytic Lymphohistocytosis (HLH): A Single Institution Experience in the Diagnosis and Management of This Variable Disease

An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Response of Patients with Aggressive Non Hodgkin's Gastro Intestinal Tract Lymphoma to Upfront Rituximab Based Chemotherapy: A Single Institution Experience.

Clinicopathologic Analysis of Primary Gastrointestinal T-Cell Lymphoma with a Special Reference to Intestinal and Gastric Type in Japan.

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only